IFNA1 and cancer: Strategies to address this issue involve minimizing the use of combined ICI treatments, utilizing Anti-IL to manage ICI arthritis without compromising immune function, employing JAK inhibitors to preserve T cell activity and anti-cancer capabilities, targeting IFN sensitivity in T cells within synovial fluid, enhancing T cell accumulation in tumors instead of joints, introducing less potent immune checkpoint inhibitors, and focusing on selectively targeting ICI antibodies to reduce systemic impact.